Cargando…

Arginase as a Mediator of Diabetic Retinopathy

We have shown previously that diabetes causes increases in retinal arginase activity that are associated with impairment of endothelial cell (EC)-dependent vasodilation and increased formation of the peroxynitrite biomarker nitrotyrosine. Arginase blockade normalizes vasodilation responses and reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Chintan, Rojas, Modesto, Narayanan, S. Priya, Zhang, Wenbo, Xu, Zhimin, Lemtalsi, Tahira, Jittiporn, Kanjana, Caldwell, R. William, Caldwell, Ruth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699717/
https://www.ncbi.nlm.nih.gov/pubmed/23840196
http://dx.doi.org/10.3389/fimmu.2013.00173
_version_ 1782275445244297216
author Patel, Chintan
Rojas, Modesto
Narayanan, S. Priya
Zhang, Wenbo
Xu, Zhimin
Lemtalsi, Tahira
Jittiporn, Kanjana
Caldwell, R. William
Caldwell, Ruth B.
author_facet Patel, Chintan
Rojas, Modesto
Narayanan, S. Priya
Zhang, Wenbo
Xu, Zhimin
Lemtalsi, Tahira
Jittiporn, Kanjana
Caldwell, R. William
Caldwell, Ruth B.
author_sort Patel, Chintan
collection PubMed
description We have shown previously that diabetes causes increases in retinal arginase activity that are associated with impairment of endothelial cell (EC)-dependent vasodilation and increased formation of the peroxynitrite biomarker nitrotyrosine. Arginase blockade normalizes vasodilation responses and reduces nitrotyrosine formation, suggesting that overactive arginase contributes to diabetic retinopathy by reducing NO and increasing oxidative stress. We tested this hypothesis by studies in streptozotocin-induced diabetic mice and high glucose (HG) treated retinal ECs. Our results show that arginase activity is increased in both diabetic retinas and HG-treated retinal ECs as compared with the controls. Western blot shows that both arginase isoforms are present in retinal vessels and ECs and arginase I is increased in the diabetic vessels and HG-treated retinal ECs. Nitrate/nitrite levels are significantly increased in diabetic retinas, indicating an increase in total NO products. However, levels of nitrite, an indicator of bioavailable NO, are reduced by diabetes. Imaging analysis of NO formation in retinal sections confirmed decreases in NO formation in diabetic retinas. The decrease in NO is accompanied by increased [Formula: see text] formation and increased leukocyte attachment in retinal vessels. Studies in knockout mice show that arginase gene deletion enhances NO formation, reduces [Formula: see text] and prevents leukostasis in the diabetic retinas. HG treatment of retinal ECs also reduces NO release, increases oxidative stress, increases ICAM-1, and induces EC death. Arginase inhibitor treatment reverses these effects. In conclusion, diabetes- and HG-induced signs of retinal vascular activation and injury are associated with increased arginase activity and expression, decreased bioavailable NO, and increased [Formula: see text] formation. Blockade of the arginase pathway prevents these alterations, suggesting a primary role of arginase in the pathophysiological process.
format Online
Article
Text
id pubmed-3699717
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-36997172013-07-09 Arginase as a Mediator of Diabetic Retinopathy Patel, Chintan Rojas, Modesto Narayanan, S. Priya Zhang, Wenbo Xu, Zhimin Lemtalsi, Tahira Jittiporn, Kanjana Caldwell, R. William Caldwell, Ruth B. Front Immunol Immunology We have shown previously that diabetes causes increases in retinal arginase activity that are associated with impairment of endothelial cell (EC)-dependent vasodilation and increased formation of the peroxynitrite biomarker nitrotyrosine. Arginase blockade normalizes vasodilation responses and reduces nitrotyrosine formation, suggesting that overactive arginase contributes to diabetic retinopathy by reducing NO and increasing oxidative stress. We tested this hypothesis by studies in streptozotocin-induced diabetic mice and high glucose (HG) treated retinal ECs. Our results show that arginase activity is increased in both diabetic retinas and HG-treated retinal ECs as compared with the controls. Western blot shows that both arginase isoforms are present in retinal vessels and ECs and arginase I is increased in the diabetic vessels and HG-treated retinal ECs. Nitrate/nitrite levels are significantly increased in diabetic retinas, indicating an increase in total NO products. However, levels of nitrite, an indicator of bioavailable NO, are reduced by diabetes. Imaging analysis of NO formation in retinal sections confirmed decreases in NO formation in diabetic retinas. The decrease in NO is accompanied by increased [Formula: see text] formation and increased leukocyte attachment in retinal vessels. Studies in knockout mice show that arginase gene deletion enhances NO formation, reduces [Formula: see text] and prevents leukostasis in the diabetic retinas. HG treatment of retinal ECs also reduces NO release, increases oxidative stress, increases ICAM-1, and induces EC death. Arginase inhibitor treatment reverses these effects. In conclusion, diabetes- and HG-induced signs of retinal vascular activation and injury are associated with increased arginase activity and expression, decreased bioavailable NO, and increased [Formula: see text] formation. Blockade of the arginase pathway prevents these alterations, suggesting a primary role of arginase in the pathophysiological process. Frontiers Media S.A. 2013-07-03 /pmc/articles/PMC3699717/ /pubmed/23840196 http://dx.doi.org/10.3389/fimmu.2013.00173 Text en Copyright © 2013 Patel, Rojas, Narayanan, Zhang, Xu, Lemtalsi, Jittiporn, Caldwell and Caldwell. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Immunology
Patel, Chintan
Rojas, Modesto
Narayanan, S. Priya
Zhang, Wenbo
Xu, Zhimin
Lemtalsi, Tahira
Jittiporn, Kanjana
Caldwell, R. William
Caldwell, Ruth B.
Arginase as a Mediator of Diabetic Retinopathy
title Arginase as a Mediator of Diabetic Retinopathy
title_full Arginase as a Mediator of Diabetic Retinopathy
title_fullStr Arginase as a Mediator of Diabetic Retinopathy
title_full_unstemmed Arginase as a Mediator of Diabetic Retinopathy
title_short Arginase as a Mediator of Diabetic Retinopathy
title_sort arginase as a mediator of diabetic retinopathy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699717/
https://www.ncbi.nlm.nih.gov/pubmed/23840196
http://dx.doi.org/10.3389/fimmu.2013.00173
work_keys_str_mv AT patelchintan arginaseasamediatorofdiabeticretinopathy
AT rojasmodesto arginaseasamediatorofdiabeticretinopathy
AT narayananspriya arginaseasamediatorofdiabeticretinopathy
AT zhangwenbo arginaseasamediatorofdiabeticretinopathy
AT xuzhimin arginaseasamediatorofdiabeticretinopathy
AT lemtalsitahira arginaseasamediatorofdiabeticretinopathy
AT jittipornkanjana arginaseasamediatorofdiabeticretinopathy
AT caldwellrwilliam arginaseasamediatorofdiabeticretinopathy
AT caldwellruthb arginaseasamediatorofdiabeticretinopathy